MaxCyte (MXCT) has released an update.
MaxCyte Inc., a leader in cell-engineering, has reported that their Non-Executive Director, John Johnston, has exercised options for 3,000 shares of common stock and subsequently sold them, reducing his holdings to 0.1% of the company. These transactions were carried out under a pre-arranged trading plan, with shares sold at prices ranging from $4.230 to $4.350. This move comes as part of Johnston’s trading plan established in December 2023, ahead of option expirations in July 2027.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
